
|Videos|October 11, 2016
Promising Alzheimer Antibody-Based Immunotherapy
Author(s)Bobby Lazzara, MD
Dr. Bobby Lazzara reports on a clinical trial of aducanumab, a human monoclonal antibody, in patients with prodromal or mild Alzheimer disease.
Advertisement
Aducanumab, a human monoclonal antibody, selectively targets aggregated amyloid-β. In this Medical News Minute, developed exclusively for Neurology Times, Dr. Bobby Lazzara discusses a
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Expands Indication for n‐Butyl Cyanoacrylate in Chronic Subdural Hematoma
2
What the First Intrathecal Gene Therapy Means for SMA Clinicians and Researchers
3
Exploring the Integration of AI into the field of Epilepsy: Balu Krishnan, MD
4
Phase 3b STRENGTH Trial Provides Greater Support for Intrathecal SMA Gene Therapy
5




















